Treatment for eating disorders : 5-HT4 receptors
Référence
85584-01
Mots-clés
Statut des brevets
French patent application FR0213725 filed on October 31, 2002 and entitled “Composition pharmaceutique pour la préparation d’un médicament destiné à traiter et/ou prévenir une pathologie liée à une conduite obsessionnelle”
Inventeurs
Valérie COMPAN
Statut commercial
Exclusive or non-exclusive licenses and collaborative research.
Laboratoire
Centre CNRS-INSERM de Pharmacologie-Endocrinologie (CCIPE, UPR9023), Montpellier, France.
Description
TECHNICAL DESCRIPTION
The invention describes the role of 5-HT4 receptors.
The inventors have performed tests in mice and have shown that inactivation of the 5-HT4 receptors helps to a decrease sensitivity to stress-induced anorexia.
INDUSTRIAL APPLICATIONS
5-HT4 receptor antagonists could be used to treat Anorexia and decrease sensitivity to drug abuse. Moreover, 5-HT4 receptor agonists could be used to treat bulimia and hyperphagia.
Besoin de plus d'informations ?
Nous contacterTechnologies Liées
-
29.10.2014
New heterocycle derivatives useful for the treatment of neurodegenerative diseases
Health / Therapeutic 02056-01
-
15.09.2014
Use of adenine-derived compounds for the treatment of systemic lupus erythematosus (sle) rare disease
Health / Therapeutic 00472-01
-
03.10.2013
Use of chlorine guanabenz derivatives for treating polyglutamines expansion associated diseases
Health / Therapeutic 86877-07